Refractory Leukemia

Actinium Pharmaceuticals Announces Filing Of Provisional Patent Application Related To Commercial Scale Labeling And ...
Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it has filed a provisional ... Read News

Salvage Therapy Of refractory And Relapsed Acute leukemia ...
Leukemia Research 23 (1999) 695–700 Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine ... Fetch Content

HIGHLIGHTS OF PRESCRIBING INFORMATION Refractory CLL ...
HIGHLIGHTS OF PRESCRIBING INFORMATION patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate. (1.2) for the treatment of patients with CLL refractory to fludarabine and alemtuzumab. (1.3) ... Read Content

Mantle Cell Lymphoma: Relapsed/Refractory
Mantle Cell Lymphoma: Relapsed/Refractory Overview Mantle cell lymphoma (MCL) is an uncommon form of non-Hodg-kin lymphoma (NHL), constituting about 6 percent of all NHL cases ... Access This Document

Chronic Lymphocytic Leukemia, or CLL. CLL is a common blood cancer, expected to take 4,650 lives in the United States this year. Most cases of CLL start in white blood cells called B-cells that have a protein called CD20 on their surface. ... Read Article

High-dose Cytosine Arabinoside And Etoposide: An Effective ...
Anthracyclines in relapsed or refractory acute leukemia to that seen with Ara-C. Although preclinical and clinical data. High-dose Ara-C and etoposide for childhood leukemia JA Whitlock et al 188 suggest that both Ara-C and etoposide have significant dose phoma: a Childrens Cancer Group study. ... Access Full Source

Refractory CML Swami Iyer - YouTube
Refractory CML Swami Iyer TheMedalGroup. Subscribe Subscribed Unsubscribe 94 94. Loading What are refractory products? - Duration: 3:01. RHI AG 12,630 views. Jamie is Living with Chronic Myelogenous Leukemia Despite the Odds - Duration: 2:06. PhRMAPress 8,347 views. ... View Video

Cellular Immunotherapy For refractory Hematological Malignancies
(Continued from previous page) Discussion: Cellular Immunotherapy for Refractory Hematological Malignancies provides a novel treatment for patients with relapsed/refractory acute leukemia or aggressive lymphoma. ... Fetch Document

Open Access Economic Analysis Of Alemtuzumab (MabCampath ) In ...
Open Access Economic Analysis of Alemtuzumab (MabCampath®) in Fludarabine-refractory Chronic Lymphocytic Leukemia N. Mittmann*,1, P.K. Isogai1, J.M. Connors2, M. Rebeira3 and M.C. Cheung4 1Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Health Sciences Centre, University ... Document Viewer

Phase I Study Of Bortezomib In Refractory Or Relapsed Acute ...
Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias Jorge Cortes,1 Deborah Thomas,1 Charles Koller,1 Francis Giles,1 Elihu Estey,1 Stefan Faderl,1 ... Read Document

Treatment Of Relapsed Or refractory Acute Promyelocytic leukemia
7 Treatment of relapsed or refractory acute promyelocytic leukemia Martin S. Tallman* MD Professor of Medicine Northwestern University Feinberg School of Medicine, Division of Hematology-Oncology, Robert H. Lurie ... Fetch Document

Targeting Vascular Endothelial Growth Factor For Relapsed And ...
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795– 801. Clinical Cancer Research 3585. ... Read Full Source

Genmab Provides Update On Ofatumumab Development In Autoimmune Indications
Company Announcement ... Read News

Myelofibrosis - Wikipedia, The Free Encyclopedia
Myelofibrosis, also known as osteomyelofibrosis, is a rare bone marrow cancer. [1] It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic stem cells in the bone marrow and other sites results in fibrosis, or the replacement ... Read Article

Current Treatment Of The Leukemias - YouTube
The treatment of relapsed/refractory chronic lymphocytic leukemia - Duration: 2:22. VJHemOnc – Video Journal of Hematological Oncology 70 views. 2:22 TM 2012 (Teaser) | Tough Mudder - Duration: 1:45. Tough Mudder 7,420,761 views. 1:45 ... View Video

Emerging Strategies For High-risk And Relapsed/refractory ...
REVIEW Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials ... Fetch Here

Juno Therapeutics - Wikipedia, The Free Encyclopedia
Drug Notes Ref; JCAR014: Currently in Phase I/II trials at the Fred Hutchison Cancer Research Center, tested for relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia ... Read Article

LY573636-Sodium For Relapsed Or Refractory Acute Myeloid Leukemia
Protocol 2008-08R UNIVERSITY OF MINNESOTA BLOOD AND TRANSPLANT MARROW PROGRAM LY573636-Sodium for Relapsed or Refractory Acute Myeloid Leukemia ... Retrieve Doc

Tolero Pharmaceuticals To Present At The 13th Annual BIO Asia International Conference
Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious oncological and hematological diseases announced today that it will present at the 13th Annual BIO Asia International Conference taking place March 15-16, 2016 at the Grand Hyatt, Tokyo, Japan. ... Read News

Recurrent/Refractory Solid Tumors And Leukemias
Recurrent/Refractory Solid Tumors and Leukemias Short Title: ADVL0921 UIC IRB Number: 2011-0367 Summary This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. ... Fetch Doc

Fludarabine-induced Bradycardia In A Patient With refractory ...
Letters Hematol Oncol Stem Cell Ther 3(2) Second Quarter 2010 hemoncstem.edmgr.com 99 Fludarabine-induced bra-dycardia in a patient with refractory leukemia ... Read Here

Secondary Myelodysplastic Syndrome And Leukemia Following I ...
Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma Brian Weiss, MD, Amish Vora, MD, John Huberty, MSc, Methods: Of 95 children with refractory neuroblastoma treated ... Read Here

Phase I Study Of Sorafenib In Patients With refractory Or ...
Or refractory acute leukemias. Design and Methods Fifty patients received one of two different schedules; Schedule “A”: once or twice daily, five leukemia cells but also in activation of the apoptotic path - way through upregulation of pro-apoptotic proteins like ... Read More

Www.fda.gov
In relapsed or refractory acute promyelocytic leukemia (APL) Your Goal: Molecular Remission TRISENOX (arsenic trioxide) is indicated for induction ... Visit Document

Inotuzumab INO-VATE ALL Study Backgrounder - Pfizer
INO-VATE ALL STUDY 1022: A PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN VERSUS INVESTIGATOR’S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA* Inotuzumab ozogamicin is an investigational agent and has not been approved by regulatory agencies. ... Read Full Source

Targeting RUNX1-Mutated Refractory AML
Acute myeloid leukemia (AML) that harbors a RUNX1 mutation, but is cytogenically normal, has a marrow, spleen, and peripheral blood.2 As patients with this type of AML, the leukemia mice were refractory to anthracycline-based chemotherapy. Even though the chemotherapy resulted in ... Read More

CAR T-Cell Therapy Engineers Your Own Cells
Investigators working in this field caution that there is still much to learn about CAR T-cell therapy. tested in relapsed and refractory non-Hodgkin lymphoma, myeloma, and chronic therapy for certain B-cell malignancies such as ALL and chronic lymphocytic leukemia. ... Read Article

High-Dose Cyclophosphamide For The Treatment Of Refractory T ...
High-Dose Cyclophosphamide for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia in Children Rachel Kobos, MD, Neerav Shukla, MD, Thomas Renaud, MD, Susan E. Prockop, MD, ... Content Retrieval